HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA sunscreen rule

This article was originally published in The Rose Sheet

Executive Summary

FDA is extending the comment period for its proposed sunscreen regulation to Dec. 26, 2007; the 90-day comment period initially was set to end Nov. 26. The proposed rule will amend the 1999 FDA final rule on sunscreens that block UVB rays to incorporate new testing and labeling requirements for products that protect against UVA rays (1"The Rose Sheet" Aug. 27, 2007, p. 3). The extension is in response to nine requests submitted to extend the comment period; eight of the requests were for an additional nine months in order to conduct laboratory testing and consumer studies on the proposed labeling system. "By extending the comment period for 30 days, FDA is balancing industry concerns and the interests of public health to ensure that sunscreen products properly inform customers of the level of protection they provide against UVA and UVB rays," the agency says Nov. 27...

You may also be interested in...



Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity

FDA's proposed rule amending its final monograph on sunscreens to include UVA ray protection standards could create new marketing opportunities for manufacturers

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.

FDA Action Items For CBD Policy? The List Is Short Due To 'Critical' Data Gaps

FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."

UsernamePublicRestriction

Register

RS015105

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel